Clinical Trials

Studies demonstrate efficacy and safety of VisonacTM and the potential for a simplified Photodynamic Therapy (PDT) procedure for treatment of moderate to severe acne Oslo, Norway, August 27, 2008 – Photocure announces positive preliminary results...

Study led by Hollings Cancer Center researcher finds risk greatest in ages 25-44 CHARLESTON, S.C., Aug. 26 /PRNewswire/ -- Individuals with a history of nonmelanoma skin cancer (NMSC), especially those who had it at a younger age, are at...

STANFORD, Calif.--(BUSINESS WIRE)--Aug 26, 2008 - Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins. Doctors have known the disease is caused by an autoimmune attack on the pancreas, but the...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 26, 2008 - The Medicines Company (NASDAQ: MDCO) today announced that the results of VELOCITY, a pivotal Phase 3 safety and efficacy trial of its new intravenous (IV) therapy Cleviprex(TM) (clevidipine...

  Studies from pramipexole clinical programme confirm efficacy in treating highly prevalent RLS-associated symptoms, including limb pain and mood disturbance Ingelheim, Germany, 26 August 2008 – Results from a large pramipexole trial programme in...

VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness ROCKVILLE, Md., Aug. 26, 2008 /PRNewswire-FirstCall/ -- Novavax, Inc. announced today favorable results from the second stage of...

STOCKHOLM, SWEDEN, August 26, 2008 - Pharmalink AB today announces positive results from a follow-on Phase III study of Xepol®, its candidate for the treatment of post-polio syndrome (PPS). The data have shown the candidate to be effective and...

STANFORD, Calif.--(BUSINESS WIRE)--Aug 26, 2008 - Previously unrecognized and unidentified infections of amniotic fluid may be a significant cause of premature birth, according to researchers at the Stanford University School of Medicine. An...

BALTIMORE, August 26, 2008 /PRNewswire-USNewswire/ -- Data by Dr. Bart Classen in The Open Endocrinology Journal provides further evidence that epidemics of childhood obesity, type 2 diabetes and metabolic syndrome are the result of exposure to the...

JERUSALEM--(BUSINESS WIRE)--Aug 26, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announces that results of the phase III ADAGIO trial were presented today during the 12th Congress of European Federation of Neurological Societies (EFNS)...

PROUD is the first study to combine early versus delayed pramipexole treatment with a parallel imaging arm to investigate potential clinical benefits of early treatment of patients with Parkinson’s disease MADRID, Spain, 25 August 2008 – Data...

EXTON, Pa., August 25, 2008 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. announced today results from a prospective, open label, Phase II study (IT-R-007) of Isolagen Therapy(TM) for the treatment of facial wrinkles and creases in approximately 40...

LONDON, Aug. 24, 2008--The global threat of extensively drug-resistant tuberculosis (XDR TB) could be managed with aggressive treatment programmes, reducing the mortality associated with the condition and preventing further transmission. These are...

INDIANAPOLIS, August 25, 2008 /PRNewswire/ -- Data from a new study suggest that Cymbalta (duloxetine HCl) 60-120 mg once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) 24-hour average pain score,...

PALO ALTO, Calif., August 21, 2008 /PRNewswire-FirstCall/ -- Telik, Inc. announced today that its novel small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of...

FREMONT, Calif.--(BUSINESS WIRE)--Aug 22, 2008 - ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced the results of a Phase 2b clinical trial testing the safety and efficacy of its prokinetic agent, ATI-7505, in...

  LONDON, Aug. 20, 2008--A new drug for cystic fibrosis, PTC124, can bypass the genetic defect in the protein-making machinery of patients and improve the functioning of cell membranes that is normally hampered by the condition. These are the...

WEIZMANN SCIENCE PARK, NESS ZIONA, Israel--(BUSINESS WIRE)--Aug. 21, 2008 - Kamada (TASE: KMDA), a bio-pharmaceutical company (www.kamada.com) engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced...

CORAL GABLES, Fla., Aug 21, 2008 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. today reported that animal data from a new study sponsored by scientists at the U.S. Department of Energy's Brookhaven National Laboratory appears...

New analysis of landmark study showed patients taking prasugrel had lower risk of combined endpoint of recurrent heart attack, stroke or cardiovascular death after first event than those taking clopidogrel TOKYO and INDIANAPOLIS, August 21, 2008...